Week of 19 October 2026 Equity GE HealthCare · GEHC

GE HealthCare's $945M deal is a race against a 110-minute clock

By Kate Akl, Marianne Fayad, Maya Halawi, Zihan Yin · Healthcare Services & Medical Equipment desk

What happened

On 5 October 2026, GE HealthCare (GEHC) agreed to acquire SOFIE Biosciences for $945 million in cash [1]. SOFIE makes the radioactive tracers that patients are injected with before a PET scan. It runs 15 production sites with 21 cyclotrons across the US and already manufactures GE HealthCare’s heart-imaging tracer, Flyrcado [1]. The deal also includes US rights to FAPI-74, a late-stage tracer being tested for imaging many types of cancer, and is expected to close in the first half of 2027 [1]. The company expects the acquisition to add to its revenue growth, adjusted EBIT margin, and adjusted earnings per share in its first full year of ownership [1].

What people are missing

On the surface, this is a company buying one of its suppliers. The deeper logic is physics. Tracers such as Flyrcado are made with fluorine-18, a radioactive atom with a half-life of 110 minutes [1]. In practice, a dose made at 8am has lost more than half its strength by 10am, and almost 80% by midday (our calculation). A tracer cannot be stored or shipped long distances: it has to be made close to the hospital and used the same day. Fluorine-18 sits in a useful middle ground. It lasts much longer than the other tracers commonly used for heart PET scans, which is what allows ready-made doses to be delivered from a regional site [2], but not long enough to travel far. Without a tracer on time, a PET scanner cannot be used, so supply directly affects how hospitals use imaging equipment. This suggests GE HealthCare is paying mainly for location: a network of 15 sites and 21 cyclotrons near hospitals that would be hard to rebuild quickly [1].

Why it matters

Tracers are a smaller but faster-growing part of GE HealthCare than its scanners. In the second quarter of 2026, its Pharmaceutical Diagnostics segment grew 14.6% on an organic basis, compared with 5.0% for Advanced Imaging Solutions, the segment that sells its imaging equipment [5]. Demand is also widening beyond the heart: GE HealthCare’s Vizamyl, a fluorine-18 tracer that shows amyloid plaques in the brain, now has a US label covering the selection of patients for Alzheimer’s treatments and checking whether plaques have cleared [3]. Each scan depends on a fresh dose arriving within hours, and with SOFIE, GE HealthCare would cover the chain from the cyclotron to the image [1].

What we are watching next

GE HealthCare reports third-quarter results on 28 October 2026 [4]. We are watching whether Pharmaceutical Diagnostics, which SOFIE will join, keeps growing faster than the imaging equipment business [1][5].

Sources

1. GE HealthCare — GE HealthCare to Acquire SOFIE Biosciences (5 October 2026)
2. TCTMD — FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades (2 October 2024)
3. GE HealthCare — FDA Approves Expanded Indications for Vizamyl (24 June 2025)
4. GE HealthCare — GE HealthCare to Announce Third Quarter 2026 Results on October 28, 2026 (7 October 2026)
5. GE HealthCare — GE HealthCare Reports Second Quarter 2026 Financial Results (29 July 2026)

Meridian62 notes explain what is happening and why. They are not investment advice and do not recommend buying or selling anything. Read the disclaimer.